Professur für Translationale Frauenheilkunde und Geburtshilfe

Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer. (2022) Fehm TN, Welslau M, Mueller V, Lueftner D, Schuetz F, Fasching P, Janni W, et al. Journal article, Review article Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. (2022) Meagher NS, Gorringe KL, Wakefield MJ, Bolithon A, Pang CNI, Chiu DS, Anglesio MS, et al. Journal article Return of individual genomic research results within the PRAEGNANT multicenter registry study (2022) Hübner H, Rübner M, Kurbacher C, Hadji P, Hartkopf AD, Lux MP, Huober J, et al. Journal article Therapierelevante Biomarker in der gynäkologischen Onkologie (2022) Ditsch N, Fasching P Journal article Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT (2022) Engler T, Fasching P, Lueftner D, Hartkopf AD, Mueller V, Kolberg HC, Hadji P, et al. Journal article Genetic variants in the genes of the sex steroid hormone metabolism and depressive symptoms during and after pregnancy (2022) Schneider M, Pretscher J, Goecke T, Häberle L, Engel A, Kornhuber J, Eichler A, et al. Journal article Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients with Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial (2022) Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stotzer O, Fasching P, et al. Journal article Superpixel Pre-segmentation of HER2 Slides for Efficient Annotation (2022) Öttl M, Mönius J, Marzahl C, Rübner M, Geppert CI, Hartmann A, Beckmann M, et al. Conference contribution, Conference Contribution Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial (2022) Graf J, Sickenberger N, Brusniak K, Matthies LM, Deutsch TM, Simoes E, Plappert C, et al. Journal article Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial (2022) Jerusalem G, Delea TE, Martin M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al. Journal article